The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
S-Variant SARS-CoV-2 Lineage B1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction
Open accessPublished version of a preprint
Abstract
A SARS-CoV-2 variant B1.1.7 containing mutation Δ69/70 has spread rapidly in the United Kingdom and shows an identifiable profile in ThermoFisher TaqPath RT-qPCR, S gene target failure (SGTF). We analyzed recent test data for trends and significance. Linked cycle threshold (Ct) values for respiratory samples showed that a low Ct for ORF1ab and N were clearly associated with SGTF. Significantly more SGTF samples had higher inferred viral loads between 1×107 and 1×108. Our conclusion is that patients whose samples exhibit the SGTF profile are more likely to have high viral loads, which may explain higher infectivity and rapidity of spread.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was also associated with threefold to eightfold higher upper-airway levels [199][200][201]”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
Ferguson, J., Dunn, S. J., Best, A., Mirza, J. D., Percival, B. C., Mayhew, M., Megram, O., Ashford, F. B., White, T., Moles-Garcia, E., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001216 · Cited by 70
Self-citationHow to establish an academic SARS-CoV-2 testing laboratory
Richter, A. G., Plant, T. D., Kidd, M., Bosworth, A., Mayhew, M., Megram, O., Ashworth, F., Crawford, L., White, T., Moles-Garcia, E., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00818-3 · Cited by 22 · cited 1×
“4 Background: The UK response to the SARS-CoV-2 pandemic has involved the setup of high-throughput diagnostic centres [1] operationally standardised using commercial reverse-transcriptase qualitative polymerase chain reaction (RT-qPCR) testing [2].”
BackgroundSelf-citationFerguson, J., Dunn, S. J., Best, A., et al. (2020) · medRxiv · doi:10.1101/2020.12.01.20237784 · Cited by 17
Self-citation
Research works printed but not linked: 1
- Richter, 24, Extrapolation of United Kingdom pillar 2 care home COVID-19 test data to ascertain effectiveness of lateral flow testing in low prevalence settings, medRxiv
Cited by
Sorted by citations
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
“V1, emerged in the United Kingdom and was associated with a surge of COVID-19 cases (Kidd et al., 2021; Leung et al., 2021).”
Estimating infectiousness throughout SARS-CoV-2 infection course
Jones, T. C., Biele, G., Mühlemann, B., Veith, T., Schneider, J. A., Beheim-Schwarzbach, J., Bleicker, T., Tesch, J., Schmidt, M. L., Sander, L. E., et al. (2021) · Science · doi:10.1126/science.abi5273 · Cited by 752
Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603
Ong, S. W. X., Chiew, C. J., Ang, L. W., Mak, T. M., Cui, L., Toh, M. P. H., Lim, Y. D., Lee, P. H., Lee, T. H., Chia, P. Y., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab721 · Cited by 430
“7 has been shown in multiple studies to have increased respiratory shedding [12, 26, 27].”
Estimating epidemiologic dynamics from cross-sectional viral load distributions
Hay, J. A., Kennedy‐Shaffer, L., Kanjilal, S., Lennon, N. J., Gabriel, S., Lipsitch, M., & Mina, M. J. (2021) · Science · doi:10.1126/science.abh0635 · Cited by 228
Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2
Vogels, C. B. F., Breban, M. I., Ott, I. M., Alpert, T., Petrone, M. E., Watkins, A. E., Kalinich, C. C., Earnest, R., Rothman, J. E., de Jesus, J. G., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001236 · Cited by 225
Peng, Z., Rojas, A. L. P., Kropff, E., Bahnfleth, W. P., Buonanno, G., Dancer, S. J., Kurnitski, J., Li, Y., Loomans, M. G. L. C., Marr, L. C., et al. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.1c06531 · Cited by 223
Luo, C. H., Morris, C. P., Sachithanandham, J., Amadi, A., Gaston, D. C., Li, M., Swanson, N. J., Schwartz, M. C., Klein, E. Y., Pekosz, A. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab986 · Cited by 199
An overview of current COVID-19 vaccine platforms
Nagy, A., & Alhatlani, B. Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.061 · Cited by 185
“The first variant was reported in UK and was termed SARS-CoV-2B.1.1.7 (UK variant 20I/501Y.V1) or variant of concern, and has subsequently spread to other countries [67–69].”
InfluentialJust 2% of SARS-CoV-2−positive individuals carry 90% of the virus circulating in communities
Yang, Q., Saldi, T. K., Gonzales, P. K., Lasda, E. L., Decker, C. J., Tat, K. L., Fink, M. R., Hager, C. R., Davis, J. C., Ozeroff, C. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104547118 · Cited by 155
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Peacock, T. P., Penrice-Randal, R., Hiscox, J. A., & Barclay, W. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001584 · Cited by 155
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 150
Interferon resistance of emerging SARS-CoV-2 variants
Guo, K., Barrett, B. S., Morrison, J. H., Mickens, K. L., Vladar, E. K., Hasenkrug, K. J., Poeschla, E. M., & Santiago, M. L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203760119 · Cited by 141
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
Marc, A., Kerioui, M., Blanquart, F., Bertrand, J., Mitjà, J., Corbacho‐Monné, M., Marks, M., & Guedj, J. (2021) · eLife · doi:10.7554/elife.69302 · Cited by 146
“First, we increased the viral production parameter, p, by a factor of 2 to 100 corresponding to observed increases of 1-7 Ct value for different variants (Teyssou et al., 2021; Roquebert et al., 2021; Kidd et al., 2021).”
BackgroundInfluentialChu, V. T., Schwartz, N. G., Donnelly, M. A. P., Chuey, M. R., Soto, R. A., Yousaf, A. R., Schmitt-Matzen, E. N., Sleweon, S., Ruffin, J. D., Thornburg, N. J., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.1827 · Cited by 140
“RESULTS This study enrolled 225 persons with RT-PCR–confirmed infection (median [range] age, 29 [1-83] years; 117 female participants [52%]; 10 [4%] Asian, 6 [3%] Black or African American, 50 [22%] Hispanic or Latino, 3 [1%] Native Hawaiian or Other Pacific Islander, 145 [64%] White, and 11 [5%] multiracial individua…”
BackgroundCOVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 143
Classification and specific primer design for accurate detection of SARS-CoV-2 using deep learning
Lopez‐Rincon, A., Tonda, A. P., Mendoza‐Maldonado, L., Mulders, D. G. J. C., Molenkamp, R., Perez-Romero, C. A., Claassen, E., Garssen, J., & Kraneveld, A. D. (2021) · Scientific Reports · doi:10.1038/s41598-020-80363-5 · Cited by 137
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 121
“Viral Load High [23,36] No difference [38] High [49] High in animal model [63] High in reinfection case [15]”
BackgroundTherapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Recurrent SARS-CoV-2 mutations in immunodeficient patients
Wilkinson, S., Richter, A., Casey, A., Osman, H. K. E., Mirza, J. D., Stockton, J., Quick, J., Ratcliffe, L., Sparks, N., Cumley, N., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac050 · Cited by 120
“S: Δ 69–70 is also a defining mutation of the Alpha and Omicron variants and is responsible for the S-gene target failure observed in the PCR testing of alpha variant samples with TaqPath SARS-CoV-2 PCR kits (Kidd et al. 2021).”
Self-citationChanging composition of SARS-CoV-2 lineages and rise of Delta variant in England
Mishra, S., Mindermann, S., Sharma, M., Whittaker, C., Mellan, T. A., Wilton, T., Klapsa, D., Mate, R., Fritzsche, M., Zambon, M. C. F. A., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101064 · Cited by 109
“7 has higher viral loads, and thus lower Ct values, than prior lineages [27].”
BackgroundA wastewater-based epidemic model for SARS-CoV-2 with application to three Canadian cities
Nourbakhsh, S., Fazil, A., Li, M., Mangat, C. S., Peterson, S. W., Daigle, J., Langner, S., Shurgold, J. H., D’Aoust, P. M., Delatolla, R., et al. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100560 · Cited by 107
Chauhan, N., Xiong, Y., Ren, S., Dwivedy, A., Magazine, N., Zhou, L., Jin, X., Zhang, T., Cunningham, B. T., Yao, S., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04835 · Cited by 99
Isothermal amplification-assisted diagnostics for COVID-19
Felice, M. D., Falco, M. D., Zappi, D., Antonacci, A., & Scognamiglio, V. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114101 · Cited by 94
Mikszewski, A., Stabile, L., Buonanno, G., & Morawska, L. (2021) · Geoscience Frontiers · doi:10.1016/j.gsf.2021.101285 · Cited by 87
Borges, V., Sousa, C., Menezes, L., Gonçalves, A. M., Picão, M., Almeida, J. P., Vieita, M., Santos, R., Silva, A. R., Costa, M., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.10.2100130 · Cited by 73
CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern
Liang, Y., Lin, H., Zou, L., Zhao, J., Li, B., Wang, H., Lu, J., Sun, J., Yang, X., Deng, X., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01017-21 · Cited by 78
“ated with high viral loads (5) and exhibits a substantial quick transmission capability”
BackgroundKarita, H. C. S., Dong, T. Q., Johnston, C., Neuzil, K. M., Paasche‐Orlow, M. K., KISSINGER, P. J., Bershteyn, A., Thorpe, L. E., Deming, M. E., Kottkamp, A. C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42796 · Cited by 79
Brown, J. C., Goldhill, D. H., Zhou, J., Peacock, T. P., Frise, R., Goonawardane, N., Baillon, L., Kugathasan, R., Pinto, A., McKay, P. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.24.432576 · Cited by 70
Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants
Koehler, M., Ray, A., Moreira, R. A., Juniku, B., Poma, A. B., & Alsteens, D. (2021) · Nature Communications · doi:10.1038/s41467-021-27325-1 · Cited by 72
SARS-CoV-2 variants, immune escape, and countermeasures
Zhang, Y., Zhang, H. C., & Zhang, W. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0906-x · Cited by 72
A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance
Bourassa, L. A., Perchetti, G. A., Phung, Q., Lin, M. J., Mills, M. G., Roychoudhury, P., Harmon, K. G., Reed, J. C., & Greninger, A. L. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104900 · Cited by 66
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65
Zhuang, X., Tsukuda, S., Wrensch, F., Wing, P. A. C., Schilling, M., Harris, J. M., Borrmann, H., Morgan, S. B., Cane, J., Mailly, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103144 · Cited by 63
“Since the initial outbreak in the Wuhan Province of China in 2019, several variants of concern (VOCs) have been documented that show a fitness advantage in terms of their ability to transmit within the community (Caly et al., 2020; Davies et al., 2021; Kidd et al., 2021; Volz et al., 2021).”
BackgroundSARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5
Timilsina, U., Umthong, S., Ivey, E. B., Waxman, B., & Stavrou, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30609-9 · Cited by 67
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
Alkhatib, M., Svicher, V., Salpini, R., Ambrosio, F. A., Bellocchi, M. C., Carioti, L., Piermatteo, L., Scutari, R., Costa, G., Artese, A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01096-21 · Cited by 62
“It has also impaired PCR diagnosis, since this deletion can abrogate detection of the S gene by some currently available real-time (RT)-PCR assays (83).”
MethodGounant, V., Ferré, V. M., Soussi, G., Charpentier, C., Flament, H., Houhou‐Fidouh, N., Collin, G., Namour, C., Assoun, S., Bizot, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.015 · Cited by 61
“Let us keep in mind that the recently described delta strain (one of the variant strains of concern, which currently represents more than 90% of sequenced viral isolates in France(35)) was reported to be 40% to 80% more transmissible than the alpha strain(36,37); it is a viral burden being 1000-fold higher than other…”
Lee, Y. S., Wing, P. A. C., Gala, D., Noerenberg, M., Järvelin, A. I., Titlow, J., Zhuang, X., Palmalux, N., Iselin, L., Thompson, M. K., et al. (2021) · eLife · doi:10.7554/elife.74153 · Cited by 59
“…mutations in the Spike that are proposed to improve cell entry, could provide the B.1.1.7 with a replicative advantage over the early lineage VIC strain enabling its rapid dissemination across the human population ( Caly et al., 2020 ; Davies et al., 2021 ; Kidd et al., 2021 ; Volz et al., 2021 ).”
InfluentialUpdate on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile
Alkhatib, M., Salpini, R., Carioti, L., Ambrosio, F. A., D’Anna, S., Duca, L., Costa, G., Bellocchi, M. C., Piermatteo, L., Artese, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02732-21 · Cited by 64
“In particular, the H69-V70del was first detected in the Alpha VOC and is well-known to increase SARS-CoV-2 infectivity and to lead to S gene target failure by some molecular assays (41, 42).”
BackgroundSentis, C., Billaud, G., Bal, A., Frobert, É., Bouscambert‐Duchamp, M., Destras, G., Josset, L., Lina, B., Morfin, F., Gaymard, A., et al. (2022) · Viruses · doi:10.3390/v14050919 · Cited by 53
“is not yet documented if its enhanced infectivity is also related to a higher viral load as reported for other variants [5,6].”
BackgroundIncreased infections, but not viral burden, with a new SARS-CoV-2 variant
Walker, A. S., Vihta, K.-D., Gethings, O., Pritchard, E., Jones, J., House, T., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., et al. (2021) · doi:10.1101/2021.01.13.21249721 · Cited by 58
Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern
Osterman, A., Iglhaut, M., Lehner, A., Späth, P. M., Stern, M., Autenrieth, H., Muenchhoff, M., Graf, A., Krebs, S., Blum, H., et al. (2021) · Medical Microbiology and Immunology · doi:10.1007/s00430-021-00719-0 · Cited by 57
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 53
Ahmad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742167 · Cited by 46
From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz‐Esparza, G. U. (2022) · Nano-Micro Letters · doi:10.1007/s40820-021-00771-8 · Cited by 49
Wollschläger, P., Tödt, D., Gerlitz, N., Pfaender, S., Bollinger, T., Sing, A., Dangel, A., Ackermann, N., Korn, K., Ensser, A., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.025 · Cited by 47
SARS-CoV-2 and Variant Diagnostic Testing Approaches in the United States
Thomas, E., Delabat, S., Carattini, Y., & Andrews, D. M. (2021) · Viruses · doi:10.3390/v13122492 · Cited by 45
“This was enabled by the discovery that a deletion (H69-V70) in the spike (S) protein resulted in S gene target amplification failure (SGTF), while target amplification of the nucleocapsid (N) and open reading frame (ORF) 1ab gene targets were unaffected [77].”
BackgroundBiological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Hoteit, R., & Yassine, H. M. (2022) · Vaccines · doi:10.3390/vaccines10060919 · Cited by 47
“According to Ct values, virus loads in SGTF samples can be 104 times higher than those in non-SGTF samples [129].”
BackgroundResultInfluentialThe impact of Spike mutations on SARS-CoV-2 neutralizationPreprint
Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L., Pataillot-Meakin, T., Graham, C., Seow, J., Lee, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.15.426849 · Cited by 45
Lu, L., Chu, A. W., Zhang, R., Chan, W.-M., Ip, J. D., Tsoi, H., Chen, L., Cai, J., Lung, D. C., Tam, A. R., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103544 · Cited by 39
Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection
Kim, H. K., Kim, H., Lee, M. K., Choi, W. H., Jang, Y., Shin, J. S., Park, J.-Y., Bae, D. H., Hyun, S., Kim, K. H., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121460 · Cited by 44
Ong, S. W. X., Young, B. E., & Lye, D. C. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00201-2 · Cited by 37
Xiao, H., Hu, J., Huang, C., Feng, W., Liu, Y., Kumblathan, T., Tao, J., Xu, J., Le, X. C., & Zhang, H. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117000 · Cited by 39
Ibrahim, L. F., Tham, D., Chong, V., Corden, M., Craig, S. S., Buntine, P., Jani, S., Zhang, M., George, S., Kochar, A., et al. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51207 · Cited by 36
Geismar, C., Nguyen, V. G., Fragaszy, E., Shrotri, M., Navaratnam, A. M. D., Beale, S., Byrne, T., Fong, W. L. E., Yavlinsky, A., Kovar, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38869-1 · Cited by 36
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 35
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34
“Finally, mRNA-1273 (18, 19) and BNT162b2 (18, 21) vaccine-induced sera showed ;3-8-fold reductions in crossneutralization of B.1.351.”
BackgroundInfluentialBayarri‐Olmos, R., Johnsen, L. B., Idorn, M., Reinert, L. S., Rosbjerg, A., Vang, S., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Bak-Thomsen, T., et al. (2021) · eLife · doi:10.7554/elife.70002 · Cited by 34
Perchetti, G. A., Zhu, H., Mills, M. G., Shrestha, L., Wagner, C., Bakhash, S. M., Lin, M. J., Xie, H. J., Huang, M.-L. W., Mathias, P. C., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27155 · Cited by 32
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
“The delta variant spike carries seven nucleotide changes and deletions compared to the spike of the ancestral Wuhan variant.”
BackgroundInfluentialOlsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 30
Papageorgiou, V. Ε., & Tsaklidis, G. M. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.112914 · Cited by 31
“2 increased contagiousness [10], increased risk of hospitalization and ICU admission, as well as increased mortality [11–13].”
Altered Subgenomic RNA Expression in SARS-CoV-2 B.1.1.7 InfectionsPreprint
Parker, M. D., Lindsey, B., Shah, D. R., Hsu, S., Keeley, A., Partridge, D., Leary, S., Cope, A., State, A., Johnson, K., et al. (2021) · bioRxiv · doi:10.1101/2021.03.02.433156 · Cited by 33
Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants
Migueres, M., Lhomme, S., Trémeaux, P., Dimeglio, C., Ranger, N., Latour, J., Dubois, M., Nicot, F., Miédougé, M., Mansuy, J., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104969 · Cited by 30
“7 lineage using the S gene dropout depends on the local epidemiology [6], being highly correlated when the circulation of this variant is predominant [7,16].”
BackgroundMethodClinical challenges of SARS‑CoV‑2 variants (Review)
Cojocaru, C., Cojocaru, E., Turcanu, A., & Zaharia, D. C. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11343 · Cited by 29
High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern
Gravagnuolo, A. M., Faqih, L., Cronshaw, C., Wynn, J., Burglin, L., Klapper, P. E., & Wigglesworth, M. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103540 · Cited by 31
“non-vaccinated cohorts [26,35], making possible a comprehensive risk assessment for the population [19], thus, informing decision makers to undertake balanced and controlled measures [36,37].”
de Souza, A. S., Amorim, V. M. D. F., Guardia, G. D. A., dos Santos, F. F., Ulrich, H., Galante, P. A. F., de Souza, R. F., & Guzzo, C. R. (2022) · Viruses · doi:10.3390/v14040827 · Cited by 28
“4 [70,83], driven by higher viral loads (PCR Ct values) [68,84], shorter time to peak viral load (shorter incubation period [70,83]), longer viral shedding (slower decline) and abrogated neutralization capacity compared to non-Delta SARS-CoV-2 variants [43] (Table 2).”
BackgroundSurveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay
Boršová, K., Paul, E. D., Kováčová, V., Radvánszka, M., Hajdu, R., Čabanová, V., Slavíková, M., Ličková, M., Lukáčiková, Ľ., Belák, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99661-7 · Cited by 29
Ratcliff, J., Nguyen, D. V., Fish, M., Rynne, J., Jennings, A., Williams, S. V., Al-Beidh, F., Bonsall, D., Evans, A. L., Golubchik, T., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab283 · Cited by 27
Diagnosing SARS-CoV-2 with Antigen Testing, Transcription-Mediated Amplification and Real-Time PCR
Dierks, S., Bader, O., Schwanbeck, J., Groß, U., Weig, M., Mese, K., Lugert, R., Bohne, W., Hahn, A., Feltgen, N., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112404 · Cited by 26
Lee, B. U. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189804 · Cited by 26
Radu, E. L., Masseron, A., Amman, F., Schedl, A., Agerer, B., Endler, L., Penz, T., Bock, C., Bergthaler, A., Vierheilig, J., et al. (2022) · Water Research · doi:10.1016/j.watres.2022.118257 · Cited by 29
“Recent studies underline our statement that SARS-CoV-2 alpha variant presents a higher viral load in the respiratory tract as well as in stool (Frampton et al., 2021; Kidd et al., 2021; Rosenke et al., 2021).”
Fang, L., Xu, J., Zhao, Y., Fan, J., Shen, J., Liu, W., & Cao, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1228128 · Cited by 26
Teyssou, E., Soulié, C., Visseaux, B., Lambert-Niclot, S., Ferré, V. M., Marot, S., Jary, A., Sayon, S., Zafilaza, K., Leducq, V., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.04.023 · Cited by 26
Vimalanathan, S., Shehata, M., Kannan, S., Delbue, S., Dolci, M., Pariani, E., D’Alessandro, S., & Pleschka, S. (2022) · Microorganisms · doi:10.3390/microorganisms10112145 · Cited by 24
Lythgoe, K., Golubchik, T., Hall, M. D., House, T., Cahuantzi, R., MacIntyre-Cockett, G., Fryer, H. R., Thomson, L., Nurtay, A., Ghafari, M., et al. (2023) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2023.1284 · Cited by 28
Shastri, J. S., Parikh, S., Agrawal, S. R., Chatterjee, N., Pathak, M., Chaudhary, S., Sharma, C., Kanakan, A., Vivekanand, A., Vasudevan, J. S., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.631769 · Cited by 23
Kim, H. N., Yoon, S., Lim, C. S., & Yoon, J. H. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24242 · Cited by 25
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Monel, B., Planas, D., Grzelak, L., Smith, N., Robillard, N., Staropoli, I., Gonçalves, P., Porrot, F., Guivel‐Benhassine, F., Guinet, N. D., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103637 · Cited by 22
“It has alternatively been observed that alpha is associated with higher viral RNA loads than non-alpha viruses [10,11].”
Kohmer, N., Eckermann, L., Böddinghaus, B., Götsch, U., Berger, A., Herrmann, E. M., Kortenbusch, M., Tinnemann, P., Gottschalk, R., Hoehl, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245751 · Cited by 22
“Higher diagnostic sensitivity is likely attributable to higher virus concentrations observed in patients infected with the Alpha variant, also observed elsewhere [28,29].”
BackgroundSARS-CoV-2 infection and immune responses
Harne, R., Williams, B., Abdelaal, H. F. M., Baldwin, S. L., & Coler, R. N. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023015 · Cited by 21
Fast detection of SARS-CoV-2 variants including Omicron using one-step RT-PCR and Sanger sequencing
Bloemen, M., Rector, A., Swinnen, J., Ranst, M. A. V., Maes, P., Vanmechelen, B., & Wollants, E. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114512 · Cited by 20
Chen, Y., Mason, G. H., Scourfield, D. O., Greenshields‐Watson, A., Haigh, T. A., Sewell, A. K., Long, H. M., Gallimore, A., Rizkallah, P. J., MacLachlan, B. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112827 · Cited by 23
Loconsole, D., Sallustio, A., Accogli, M., Leaci, A., Sanguedolce, A., Parisi, A., & Chironna, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.007 · Cited by 20
“It is hypothesized that SARS-CoV-2 variants are capable of at least partially evading vaccine-induced immunity, and that they replicate more efficiently [8]; in fact, all vaccinated cases described herein had a high viral load (Ct < 21).”
Parker, M. D., Stewart, H., Shehata, O. M., Lindsey, B. B., Shah, D. R., Hsu, S. N., Keeley, A. J., Partridge, D. G., Leary, S., Cope, A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03565-9 · Cited by 49
Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load
Kennedy‐Shaffer, L., Kahn, R. J., & Lipsitch, M. (2021) · Epidemiology · doi:10.1097/ede.0000000000001415 · Cited by 19
Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far
Alsafi, R. (2022) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2022/1156273 · Cited by 24
Intra-Host Evolution Provides for Continuous Emergence of SARS-CoV-2 Variants
Landis, J. T., Moorad, R., Pluta, L., Caro‐Vegas, C., McNamara, R. P., Eason, A. B., Bailey, A., Villamor, F. C. S., Juarez, A., Wong, J. P., et al. (2021) · mBio · doi:10.1128/mbio.03448-22 · Cited by 20
SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition
Altmann, D. M., Reynolds, C. J., & Boyton, R. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100286 · Cited by 19
“Implicated mechanisms rest largely on the notion of improved binding to ACE2 and increased viral load in nasopharyngeal samples.(5) There has been concern and speculation about the possibility that some of these mutations may facilitate immune evasion, with implications both for risk of reinfection in those previously…”
BackgroundWang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19
Alpha variant SARS-CoV-2 infection: How it all starts
Domingo, P., & Benito, N. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103703 · Cited by 18
“Mechanistic explanations for its enhanced transmissibility included higher nasopharyngeal viral load and prolonged viral shedding [4,5].”
BackgroundKováčech, B., Fialová, Ľ., Filipčík, P., Škrabana, R., Žilková, M., Ivanovova, N. P., Kováč, A., Palova, D., Rolkova, G., Tomkova, K., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103818 · Cited by 19
One assay to test them all: Multiplex assays for expansion of respiratory virus surveillance
Boukli, N., Flamand, C., Chea, K. L., Heng, L., Keo, S., Sour, K., In, S., Chhim, P., Chhor, B., Kruy, L., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1161268 · Cited by 18
Papageorgiou, V. Ε., & Tsaklidis, G. M. (2024) · Mathematical Methods in the Applied Sciences · doi:10.1002/mma.9934 · Cited by 18
“On the other hand, the emergence of variants has been associated with increased transmissibility [13], hospitalizations, and mortality [14 – 16].”
Background
Metadata
- Authors
- Kidd, M., Richter, A., Best, A., Cumley, N., Mirza, J., Percival, B., Mayhew, M., Megram, O., Ashford, F., White, T., Moles-Garcia, E., Crawford, L., Bosworth, A., Atabani, S. F., Plant, T., & McNally, A.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of Birmingham (GB)
- Corresponding author
- Kidd, Michael
- ORCID
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-02-13
- Volume
- 223
- Issue
- 10
- Pages
- 1666-1670
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC7928763
- OpenAlex
- W3128016658
- Cited by
- 237
- References
- 3
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 12 · 2023: 31 · 2022: 67 · 2021: 116
- FWCI
- 17.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- UK Department of Health and Social Care
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, B.1.1.7 variant, S-gene target failure, viral load, cycle threshold, ORF1ab, N gene, infectivity, COVID-19 diagnosis
- MeSH terms
- COVID-19, SARS-CoV-2, Humans, Linear Models, Polymerase Chain Reaction, Viral Load, Taq Polymerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
